These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 34215691)

  • 21. Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system.
    Zhai Y; Ye X; Hu F; Xu J; Guo X; Zhuang Y; He J
    J Immunother Cancer; 2019 Nov; 7(1):286. PubMed ID: 31694698
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and Efficacy of the Rechallenge of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer: A Systemic Review and Meta-Analysis.
    Zhao Q; Zhang J; Xu L; Yang H; Liang N; Zhang L; Zhang F; Zhang X
    Front Immunol; 2021; 12():730320. PubMed ID: 34646270
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Management of immune checkpoint inhibitor-related dermatologic adverse events.
    Si X; He C; Zhang L; Liu X; Li Y; Wang H; Guo X; Zhou J; Duan L; Wang M; Zhang L
    Thorac Cancer; 2020 Feb; 11(2):488-492. PubMed ID: 31814310
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of immune-related adverse events (irAEs) and their treatment on antitumor immune responses.
    Blum SM; Rouhani SJ; Sullivan RJ
    Immunol Rev; 2023 Sep; 318(1):167-178. PubMed ID: 37578634
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical and translational attributes of immune-related adverse events.
    Suijkerbuijk KPM; van Eijs MJM; van Wijk F; Eggermont AMM
    Nat Cancer; 2024 Apr; 5(4):557-571. PubMed ID: 38360861
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry.
    Ruste V; Goldschmidt V; Laparra A; Messayke S; Danlos FX; Romano-Martin P; Champiat S; Voisin AL; Baldini C; Massard C; Laghouati S; Marabelle A; Lambotte O; Michot JM
    Eur J Cancer; 2021 Nov; 158():217-224. PubMed ID: 34627664
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical diagnosis and treatment recommendations for immune checkpoint inhibitor-related hematological adverse events.
    Zhuang J; Du J; Guo X; Zhou J; Duan L; Qiu W; Si X; Zhang L; Li Y; Liu X; Wang H; Zhou D; Zhang L
    Thorac Cancer; 2020 Mar; 11(3):799-804. PubMed ID: 32017466
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immune-Related Adverse Events by Immune Checkpoint Inhibitors Significantly Predict Durable Efficacy Even in Responders with Advanced Non-Small Cell Lung Cancer.
    Akamatsu H; Murakami E; Oyanagi J; Shibaki R; Kaki T; Takase E; Tanaka M; Harutani Y; Yamagata N; Okuda Y; Furuta K; Sugimoto T; Teraoka S; Hayata A; Tokudome N; Ozawa Y; Mori K; Koh Y; Yamamoto N
    Oncologist; 2020 Apr; 25(4):e679-e683. PubMed ID: 32297443
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis.
    Zhou X; Yao Z; Yang H; Liang N; Zhang X; Zhang F
    BMC Med; 2020 Apr; 18(1):87. PubMed ID: 32306958
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immune-Related Adverse Events as Clinical Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors.
    Martini DJ; Goyal S; Liu Y; Evans ST; Olsen TA; Case K; Magod BL; Brown JT; Yantorni L; Russler GA; Caulfield S; Goldman JM; Nazha B; Harris WB; Kissick HT; Master VA; Kucuk O; Carthon BC; Bilen MA
    Oncologist; 2021 Oct; 26(10):e1742-e1750. PubMed ID: 34156726
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors - A systematic review and meta-analysis.
    Hussaini S; Chehade R; Boldt RG; Raphael J; Blanchette P; Maleki Vareki S; Fernandes R
    Cancer Treat Rev; 2021 Jan; 92():102134. PubMed ID: 33302134
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Predictive Biomarkers of Immune-related Adverse Events Induced by Checkpoint Inhibitors in Malignancies].
    Tang H; Guan M; Sun Z; Bai CM
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2020 Dec; 42(6):825-830. PubMed ID: 33423733
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bone fracture as a novel immune-related adverse event with immune checkpoint inhibitors: Case series and large-scale pharmacovigilance analysis.
    Filippini DM; Gatti M; Di Martino V; Cavalieri S; Fusaroli M; Ardizzoni A; Raschi E; Licitra L
    Int J Cancer; 2021 Aug; 149(3):675-683. PubMed ID: 33844854
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immune-related adverse events associated with immune checkpoint inhibitors in patients with cancer.
    Sengul Samanci N; Cikman DI; Oruc K; Bedir S; Çelik E; Degerli E; Derin S; Demirelli FH; Özgüroğlu M
    Tumori; 2021 Aug; 107(4):304-310. PubMed ID: 32935638
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intestinal Microbiome Associated With Immune-Related Adverse Events for Patients Treated With Anti-PD-1 Inhibitors, a Real-World Study.
    Liu W; Ma F; Sun B; Liu Y; Tang H; Luo J; Chen H; Luo Z
    Front Immunol; 2021; 12():756872. PubMed ID: 34975845
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Correlation Between Immune-Related Adverse Events and Prognosis in Hepatocellular Carcinoma Patients Treated With Immune Checkpoint Inhibitors.
    Xu S; Lai R; Zhao Q; Zhao P; Zhao R; Guo Z
    Front Immunol; 2021; 12():794099. PubMed ID: 34950153
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Uncovering the flip side of immune checkpoint inhibitors: a comprehensive review of immune-related adverse events and predictive biomarkers.
    Miao YD; Quan WX; Tang XL; Shi WW; Li Q; Li RJ; Wang JT; Gan J; Dong X; Hao L; Luan WY; Zhang F
    Int J Biol Sci; 2024; 20(2):621-642. PubMed ID: 38169638
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immune-Related Adverse Events and Survival Among Patients With Metastatic NSCLC Treated With Immune Checkpoint Inhibitors.
    Cook S; Samuel V; Meyers DE; Stukalin I; Litt I; Sangha R; Morris DG; Heng DYC; Pabani A; Dean M; Navani V
    JAMA Netw Open; 2024 Jan; 7(1):e2352302. PubMed ID: 38236598
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immune-Related Adverse Events Requiring Hospitalization: Spectrum of Toxicity, Treatment, and Outcomes.
    Balaji A; Zhang J; Wills B; Marrone KA; Elmariah H; Yarchoan M; Zimmerman JW; Hajjir K; Venkatraman D; Armstrong DK; Laheru DA; Mehra R; Ho WJ; Reuss JE; Heng J; Vellanki P; Donehower RC; Holdhoff M; Naidoo J
    J Oncol Pract; 2019 Sep; 15(9):e825-e834. PubMed ID: 31386608
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Exploring the Landscape of Immune Checkpoint Inhibitor-Induced Adverse Events Through Big Data Mining of Pan-Cancer Clinical Trials.
    Fadlullah MZH; Lin CN; Coleman S; Young A; Naqash AR; Hu-Lieskovan S; Tan AC
    Oncologist; 2024 May; 29(5):415-421. PubMed ID: 38330451
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.